April 16, 2025

RSV Vaccine Access Under CDC Review

“An estimated 15,000–20,000 annual RSV-associated hospitalizations occur in adults aged 50–59”—prompting CDC advisers to revisit age-based vaccine recommendations.

Reuters

April 16, 2025

CONSORT 2025: Setting New Standards for Clinical Trial Reporting

"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.

Conexiant

April 15, 2025

Coadministration of RSV and COVID-19 Vaccines Safe, Study

Coadministration of mRNA-1345 with a standard-dose quadrivalent inactivated influenza vaccine or bivalent mRNA-1273.214 COVID-19 vaccine was generally safe and elicited mostly noninferior immune responses in adults aged 50 years and older.

Conexiant

April 15, 2025

ACIP to Weigh COVID, RSV, Measles Shots

The CDC's expert panel convenes to discuss next-gen COVID-19 shots and vaccination guidelines for various diseases amid a US measles outbreak.

Reuters

April 14, 2025

FDA-Approved COVID-19 Drugs: Safety Risks Assessed

Researchers found most FDA-authorized COVID-19 treatments were not linked to serious adverse events, though risks may rise with tocilizumab or convalescent plasma in specific patients.

Conexiant

April 03, 2025

Patterns in Adherence to USPSTF Lung Cancer Screening Guidelines

In a study reported as a research letter in JAMA Oncology, Rolle et al found increased overall adherence to the 2021 updated U.S. Preventive Services Task Force (USPSTF) lung cancer screening guidelin...

The ASCO Post

April 03, 2025

Study Reveals Psychiatric Sequelae Post-COVID-19

COVID-19 survivors showed a significantly higher risk of psychiatric disorders, according to a recent study.

Conexiant

April 02, 2025

New Antibody Lowers COVID-19 Cases in Trial

Sipavibart reduced symptomatic COVID-19 by 34.9% compared to standard treatment, but efficacy was only observed against non–Phe456Leu-containing variants, according to new phase 3 trial data.

Conexiant

April 02, 2025

FDA Misses Novavax Decision Date

FDA misses April 1 deadline for deciding on Novavax's COVID-19 vaccine.

Reuters